Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|September 27, 2011
XDS MasterLab - FOSS NIRSystems, Inc
Content Uniformity Made Easy The FOSS MasterLab is based on XDS Near-Infrared (NIR) technology and provides pharmaceutical manufacturers with a rapid, reliable and non-destructive test method covering the full array of solid dosage forms: layered, coated or cored tablets, capsules, caplets, geltabs and gelcaps. The versatile sampling mechanism of the MasterLab offers an automated and unattended reflectance or transmission analysis of a tray of multiple tablets or vials. Visit FOSS NIRSystems Learn more about the XDS MasterLab Contact Us
Advertisement
Content Uniformity Made Easy
The FOSS MasterLab is based on XDS Near-Infrared (NIR) technology and provides pharmaceutical manufacturers with a rapid, reliable and non-destructive test method covering the full array of solid dosage forms: layered, coated or cored tablets, capsules, caplets, geltabs and gelcaps.
The versatile sampling mechanism of the MasterLab offers an automated and unattended reflectance or transmission analysis of a tray of multiple tablets or vials.
Advertisement
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
AAPS PharmSci 360 2026: E&L Standards Harmonization
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5